Abstract:Despite the advances in treatment strategies, cancer is still the second leading cause of death in the USA. A majority of the currently used cancer drugs have limitations in their clinical use due to poor selectivity, toxic side effects and multiple drug resistance, warranting the development of new anticancer drugs of different mechanisms of action. Here we describe the design, synthesis and initial biological evaluation of a new class of antimitotic agents that modulate tubulin polymerization. Structurally, these compounds are chalcone mimics containing a 1-(1H-imidazol-2-yl)ethan-1-one moiety, which was initially introduced to act as a metal-binding group and inhibit histone deacetylase enzymes. Although several analogues selectively inhibited purified HDAC8 with IC50 values in low micromolar range, tissue culture studies suggest that HDAC inhibition is not a major mechanism responsible for cytotoxicity. The compounds demonstrated cell growth inhibition with GI50 values of upper nanomolar to low micromolar potency with significant selectively for cancer over normal cells. Interestingly, several compounds arrested HeLaM cells in mitosis and seem to target tubulin to cause mitotic arrest. For example, when combined with inhibitors of Aurora B kinase, they led to dramatic disassembly of the mitotic spindle. In-vitro tubulin polymerization studies showed that the compounds reduced the rate of polymerization of microtubules during the elongation phase and lowered the amount of polymerized tubulin during the plateau phase. Finally, in silico docking studies identified binding of IPE-7 to the colchicine site with similar affinity as the test compound D64131. These compounds represent a new antimitotic pharmacophore with limited HDAC inhibitory activity.

Computational Approaches to the Rational Design of Tubulin-Targeting Agents

Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Discovery of Novel Tubulin Polymerization Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Studying drug-tubulin interactions by X-ray crystallography

Development of tubulin polymerization inhibitors as anticancer agents

Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site.

High-resolution X-ray Structure of Three Microtubule-Stabilizing Agents in Complex with Tubulin Provide a Rationale for Drug Design.

Tubulin degradation: Principles, agents, and applications

Tubulin/HDAC dual-target inhibitors: Insights from design strategies, SARs, and therapeutic potential

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy

Structure-based approaches for the design of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d][1,2,3]triazoles as tubulin polymerization inhibitors

In silico design of a new Podophyllotoxin derivative with potent anti-tubulin activity

X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone As Potent Tubulin Polymerization Inhibitors.

A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin

A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics

The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues

Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Containing Derivatives As Potential Tubulin Assembling Inhibitors

Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site

Design, Synthesis, Biological Evaluation, and 3D-QSAR Analysis of Podophyllotoxin-Dioxazole Combination As Tubulin Targeting Anticancer Agents.

Drugs that target dynamic microtubules: A new molecular perspective